Skip to main content
SpringerLink
Log in

p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

  • Original Paper
  • Published:
Pathology & Oncology Research

Abstract

The objective of this study was to verify the frequency of p53 and BCL-2 immunohistochemical expression in patients with endometrial carcinoma and to correlate it with histological factors (histological type, tumor grade, depth of myometrial invasion, lymph node involvement and surgical staging) and survival. Forty-eight patients with endometrial carcinoma who were submitted to primary surgical treatment were assessed. p53 and BCL-2 immunohistochemical expression was determined using paraffin blocks containing the tumor area. p53 and BCL-2 expression was detected in 39.6% and 58.3% of the tumors, respectively. No significant difference was found regarding the frequency of p53 expression when analyzing histological type (33.3% in endometrioid tumors, 58.3% in non-endometrioid tumors; p = 0.176), depth of myometrial invasion (p = 0.632) and surgical staging (I—11.1%, II—66.7%, III—57.1%; p = 0.061). p53 expression was significantly more frequent in undifferentiated tumors (p = 0.007) and in those showing lymph node involvement (p = 0.030). Univariate analysis showed a positive association with death (RR, 3.358; CI, 1.386–8.134; p = 0.005) and short-term survival. The present study did not reveal any correlation between BCL-2 expression and histopathologic markers or survival. In conclusion, this study showed that p53 expression is directly correlated with undifferentiated tumors, lymph-node involvement and risk of death. On the other hand, BCL-2 expression was not correlated with any known histological factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Instituto Nacional do Câncer. (2006) Estimativas da Incidência e mortalidade por câncer no Brasil. 2003. http://www.inca.gov.br. Accessed May 2

  2. Hacker NF (2000) Uterine cancer. In: Berek JS and Hacker NF (eds) Practical gynecologic oncology, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, pp 407–456

    Google Scholar 

  3. Axtell LM, Myers MH (1978) Contrasts in survival of black and white cancer patients. J Natl Cancer Inst 60:1209–1215

    PubMed  CAS  Google Scholar 

  4. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33

    Article  PubMed  CAS  Google Scholar 

  5. Mariani A, Sebo TJ, Katzmann JA, Keeney GL, Roche PC, Lesnick TG, Podratz KC (2000) Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 182:1535–1544

    Article  PubMed  CAS  Google Scholar 

  6. Ohkouchi T, Sakuragi N, Watari H, Nomura E, Todo Y, Yamada H, Fujimoto S (2002) Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol 187:353–359

    Article  PubMed  CAS  Google Scholar 

  7. Geisler JP, Wiemann MD, Zhou Z, Miller GA, Geisler HE (1996) p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61:245–248

    Article  PubMed  CAS  Google Scholar 

  8. Geisler JP, Geisler HE, Wiemann MD, Zhou Z, Miller GA, Crabtree W (1999) p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 74:468–471

    Article  PubMed  CAS  Google Scholar 

  9. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W (1998) Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol 71:305–307

    Article  PubMed  CAS  Google Scholar 

  10. Sakuragi N, Ohkouchi T, Hareyama H, Ikeda K, Watari H, Fujimoto T, Kuwabara M, Yamamoto R, Sagawa T, Fujino T, Fujimoto S (1998) Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 79:153–158

    Article  PubMed  CAS  Google Scholar 

  11. Nishioka H, Hiasa Y, Hayashi I, Kitahori Y, Konishi N, Sugimura M (1993) Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplasias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 50:426–429

    Article  PubMed  CAS  Google Scholar 

  12. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones M (2000) Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 13:379–388

    Article  PubMed  CAS  Google Scholar 

  13. Kohler MF, Carney P, Dodge R, Soper J, Clarke-Pearson DL, Marks JR, Berchuck A (1996) p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175:1246–1252

    Article  PubMed  CAS  Google Scholar 

  14. Morsi HM, Leers MP, Radespiel-Tröger M, Björklund V, Kabarity HE, Nap M, Jäger W (2000) Apoptosis, bcl-2 expression, and proliferation in benign and malignant endometrial epithelium: an approach using multiparameter flow cytometry. Gynecol Oncol 77:11–17

    Article  PubMed  CAS  Google Scholar 

  15. Marone M, Ferrandina G, Macchia G, Mozzetti S (2000) Bcl-2, Bax, Bcl-xl and Bcl-xs expression in neoplastic and normal endometrium. Oncology 58:161–168

    Article  PubMed  CAS  Google Scholar 

  16. Coppola D, Fu L, Nicosia SV, Kounelis S, Jones M (1998) Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Human Pathol 29:455–462

    Article  CAS  Google Scholar 

  17. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R (1996) Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 15:202–208

    PubMed  CAS  Google Scholar 

  18. Taskin M, Lallas TA, Barber HR, Shevchuk MM (1997) bcl-2 and p53 endometrial adenocarcinoma. Mod Pathol 10:728–734

    PubMed  CAS  Google Scholar 

  19. Saegusa M, Okayasu I (1997) Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol 123:429–434

    Article  PubMed  CAS  Google Scholar 

  20. College of American Pathologists (2006) http://www.cap.org. Home>reference and Publications> Cancer Protocols and Checklists. Accessed 22 May

  21. Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC (1998) Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 18:3689–3694

    PubMed  CAS  Google Scholar 

  22. van Slooten HJ, van der Vijver MJ, van der Velde CJH, van Dierendonck JH (1998) Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77:789–796

    PubMed  Google Scholar 

  23. Bonneefoy-Berard N, Aouacheria A, Verschelde C, Quemeneur L, Marçais A, Marvel J (2004) Control of proliferation by Bcl-2 family members. Biochim Biophys Acta 1644:159–168

    Article  CAS  Google Scholar 

  24. Boyd J (1996) Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes—editorial. Gynecol Oncol 61:163–165

    Article  PubMed  CAS  Google Scholar 

  25. Ambros RA, Sherman ME, Zahm CM, Bitterman P, Kurman RJ (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267

    Article  PubMed  CAS  Google Scholar 

  26. Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26:1268–1274

    Article  PubMed  CAS  Google Scholar 

  27. Spiegel GW (1995) Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 19:417–432

    Article  PubMed  CAS  Google Scholar 

  28. Burton JL, Wells M (1998) Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium—review. Histopathology 33:297–303

    Article  PubMed  CAS  Google Scholar 

  29. Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, et al (2001) Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol 83:485–490

    Article  PubMed  CAS  Google Scholar 

  30. Kohler MF, Kerns BJ, Humprey PA, Marks JR, Bast RC, Berchuck A (1993) Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643–650

    PubMed  CAS  Google Scholar 

  31. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ (1996) Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74:562–567

    PubMed  CAS  Google Scholar 

  32. Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic LA (2004) Significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 93:34–40

    Article  PubMed  CAS  Google Scholar 

  33. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L (1997) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177–185

    PubMed  CAS  Google Scholar 

  34. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799–1805

    PubMed  CAS  Google Scholar 

  35. Bonfitto VL, de Angelo Andrade LA (2003) p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy. Sao Paulo Med J 121:163–166

    Article  PubMed  Google Scholar 

  36. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622–1627

    PubMed  CAS  Google Scholar 

  37. Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC (1996) Prognostic value of p53 and proliferation cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 62:192–198

    Article  PubMed  CAS  Google Scholar 

  38. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG, Garrett CT (1994) Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 54:4667–4670

    PubMed  CAS  Google Scholar 

  39. Derossi DR, Ito K, Couto Filho J, Bacchi CE (2003) Avaliação da expressão da proteína bcl-2 no carcinoma de mama: estudo em punção aspirativa por agulha fina; correlação com grau histológico em espécimes cirúrgicos correspondentes. J Bras Patol Med Lab 39:229–235

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Hospital de Clínicas de Porto Alegre, Medical Post-Graduate Program, School of Medicine, Federal University of Rio Grande do Sul, Rua Comendador Caminha, 128/902, Porto Alegre, Rio Grande do Sul, CEP 90430-030, Brazil

    Márcia L. M. Appel, Waldemar A. Rivoire, Heleusa I. Mônego & Ricardo dos Reis

  2. Department of Pathology, Hospital de Clínicas de Porto Alegre, Medical Post-Graduate Program, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

    Maria I. Edelweiss & Luis F. Rivero

  3. Department of Clinical Oncology, Hospital de Clínicas de Porto Alegre, Medical Post-Graduate Program, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

    James Fleck

Authors
  1. Márcia L. M. Appel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria I. Edelweiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Fleck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luis F. Rivero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Waldemar A. Rivoire
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heleusa I. Mônego
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ricardo dos Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Márcia L. M. Appel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Appel, M.L.M., Edelweiss, M.I., Fleck, J. et al. p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma. Pathol. Oncol. Res. 14, 23–30 (2008). https://doi.org/10.1007/s12253-008-9000-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-008-9000-9

Keywords

Search

Navigation